Shopping Cart
- Remove All
- Your shopping cart is currently empty
Abetimus (LJP 394 free base), an immunosuppressant composed of four double-stranded DNA (dsDNA) oligonucleotides, can crosslink anti-dsDNA antibodies on B cell surfaces and reduce anti-dsDNA antibody levels, offering research potential for systemic lupus erythematosus [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | 8-10 weeks | |
50 mg | Inquiry | 8-10 weeks |
Description | Abetimus (LJP 394 free base), an immunosuppressant composed of four double-stranded DNA (dsDNA) oligonucleotides, can crosslink anti-dsDNA antibodies on B cell surfaces and reduce anti-dsDNA antibody levels, offering research potential for systemic lupus erythematosus [1]. |
In vitro | The administration of Abetimus (LJP 394 free base) is believed to reduce circulating anti-double-stranded DNA antibodies (anti-dsDNA Abs) via at least two mechanisms. |
In vivo | Abetimus (LJP 394 free base) effectively reduces anti-dsDNA-mediated disease symptoms in male BXSB mice, a systemic lupus model. Administering Abetimus at 3-300 μg/mouse intravenously twice weekly from around nine weeks of age significantly lowered anti-dsDNA antibody levels, decreased anti-dsDNA-secreting spleen cells, and improved renal histopathology compared to untreated controls [2]. Additionally, Abetimus exhibits a pharmacokinetic half-life of 40 minutes to 1 hour in mice [1]. |
Alias | LJP 394 free base |
Molecular Weight | 318.28 |
Formula | C11H18N4O7 |
Cas No. | 167362-48-3 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.